Microfluidic-assisted integrated nucleic acid test strips for POCT

Talanta. 2024 Jan 15:267:125150. doi: 10.1016/j.talanta.2023.125150. Epub 2023 Sep 3.

Abstract

Numerous diseases have posed significant threats to public health, notably the global pandemic of COVID-19, resulting in widespread devastation due to its high infectivity and severity. The nucleic acid lateral flow assay (NALFA) addresses challenges of complexity, cost, and time associated with traditional assays, offering a reliable platform for rapid and precise nucleic acid target detection. NALFA is gaining prominence as a point-of-care testing (POCT) technique, thanks to its user-friendly operation and rapid results. Nevertheless, conventional NALFA relies on specialized technicians and involves labor-intensive steps like DNA extraction and PCR processes, impeding its efficiency. To overcome these limitations, integrating NALFA with microfluidic technology, widely employed in rapid field detection, holds promise. This review comprehensively outlines prevailing strategies for integrating NALFA, encompassing both research initiatives and commercial applications. Addressing the bottleneck of nucleic acid amplification as a rate-limiting step, the review delves into progress in amplification-free NALFA and highlights prevalent signal amplification techniques. Ultimately, the review outlines the future prospect of integrated NALFA development, capturing the technology's evolution and providing valuable insights for academic and commercial endeavors.

Keywords: Nucleic acid lateral flow assay; Post-of-care testing; Rapid detection; Signal amplification; Test strips.

Publication types

  • Review

MeSH terms

  • Microfluidics
  • Nucleic Acid Amplification Techniques / methods
  • Nucleic Acids*
  • Point-of-Care Testing
  • Polymerase Chain Reaction

Substances

  • Nucleic Acids